Cocrystal Pharma Announces Passing of Board Director Dr. Anthony Japour
COCP sits 20% above its 52-week low of $0.859 on light trading volume (0.3× avg).
Summary
Cocrystal Pharma, Inc. reported the passing of Dr. Anthony Japour, a member of its board of directors, on March 10, 2026.
Key Events · Executive and Board Changes · COCP
-
Board Director Passes Away
Dr. Anthony Japour, a member of Cocrystal Pharma's board of directors, passed away on March 10, 2026.
Analysis · COCP · Life Sciences
The unexpected passing of a board director creates a vacancy and necessitates a search for a replacement, which can temporarily impact board continuity and strategic oversight. For a smaller company like Cocrystal Pharma, the loss of an experienced director may be more acutely felt, potentially affecting governance and decision-making processes until a new director is appointed.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.6% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COCP was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.2M. The 52-week trading range was $0.86 to $2.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.